LTRN · Lantern Pharma Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern in the absence of obtaining substantial additional funding. While the Company plans to pursue periodic capital raises, including additional potential sales under the ATM, as well as potential collaborations, grant funding and other opportunities to extend the Company's operating runway, no assurance can be given that sufficient funding will be available when needed to allow the Company to continue as a going concern.”View the 10-Q filed Aug 14, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $8.7M | $11.51M | $16.13M | $11.89M | $8.6M | $7.57M | $2.24M | — | |
| $6.77M | $6.46M | $6.09M | $5.98M | $5.83M | $5.02M | $3.66M | $1.48M | |
| $15.81K | $17.28K | $17.28K | $14.62K | $10.08K | $6761 | $3388 | $1627 | |
| $15.47M | $17.98M | $22.22M | $17.88M | $14.43M | $12.59M | $5.91M | $2.43M | |
| -$15.47M | -$17.98M | -$22.22M | -$17.88M | -$14.43M | -$12.59M | — | — | |
| $176.37K | $421.13K | $692.87K | $1.15M | -$31.55K | $160.55K | — | — | |
| -$18.65M | -$17.12M | -$20.78M | -$15.96M | -$14.26M | -$12.36M | -$5.91M | -$2.43M | |
| — | — | — | — | — | $12.36M | $5.91M | — | |
| — | — | — | — | — | -$12.36M | -$5.91M | — | |
| -$18.74M | -$17.25M | -$20.52M | -$15.7M | -$14.54M | -$12.46M | — | — | |
| USD/shares | -$1.62 | -$1.57 | -$1.93 | -$1.47 | -$1.31 | -$1.13 | — | — |
| USD/shares | -$1.62 | -$1.57 | -$1.93 | -$1.47 | -$1.31 | — | — | — |
| shares | — | 10.9M | 10.76M | 10.84M | 10.85M | 10.9M | 4.3M | 1.98M |
| shares | — | 10.9M | 10.76M | 10.84M | 10.85M | 10.9M | 4.3M | 1.98M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2021–FY2023: $3.92M in buybacks.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Read debt and covenant terms in your AI or your code through MCP and the API →Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Operating lease liabilities | 2026-06-30 | USD 39,715 | 10-Q filed 2026-08-14 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 214 similar-size Biotechnology companies (of 588 listed).